Ebastine
- Atc Codes:R06AX22
- CAS Codes:90729-43-4
- PHARMGKB ID:90729-43-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Ebastel, Kestine; Belgium: Estivan; Cyprus: Ebastel; Denmark: Durfin, Kestine; Estonia: Kestine; Finland: Kestine; France: Kestin, Kestinlyo; Germany: Ebastel, Ebastin, Ebastion, Kestine; Greece: Kestine; Hungary: Ebastine; Ireland: Kestine; Italy: Clever, Kestine; Latvia: Kestine; Lithuania: Kestine; Netherlands: Kestine, Netan Smelt; Poland: Alestin; Portugal: Ebastina, Ebastion, Estivan, Kestine; Spain: Alastina, Bactil, Ebastel, Ebastina; Sweden: Kestine.
Latin America
Brazil: Ebastel; Mexico: Evastel, Pinavalt.
Asia
Japan: Ebastine, Ebastel.
Drug combinations
Ebastine and Pseudoephedrine
Chemistry
Ebastine: C~32~H~39~NO~2~. Mw: 469.66. (1) 1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-; (2) 4′-tert-Butyl-4-[4-(diphenylmethoxy)piperidino]butyrophenone. CAS-90729-43-4 (1987).
Pharmacologic Category
Second Generation Antihistamines; Histamine H~1~ Antagonist. (ATC-Code: R06AX22).
Mechanism of action
A long-acting, selective H~1~-histamine receptor antagonist. After repeated administration, inhibition of peripheral receptors remains at constant level.
Therapeutic use
Indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, idiopathic chronic urticaria.
Pregnancy and lactiation implications
Safety of ebastine during pregnancy and lactation not established. Use caution.
Unlabeled use
Contraindications
Patients with known hypersensitivity to ebastine or any of its ingredients.
Warnings and precautions
Caution advised when using ebastine in patients known to have long QT syndrome, hypokalemia, treatment with any drug known to produce increase in QT interval or inhibit CYP3A4 enzyme systems such as azole antifungals and macrolide antibiotics.